U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07135323) titled 'AvertD Post-Approval Study' on July 17.

Brief Summary: A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population

Study Start Date: Nov. 15, 2024

Study Type: OBSERVATIONAL

Condition: Opioid Use Disorder

Intervention: GENETIC: Opioid Used Disorder Risk Assessment

Determine the likelihood of Opioid Used Disorder prior to prescribing opioids

Recruitment Status: RECRUITING

Sponsor: Prescient Medicine Holdings, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....